News
Linkfluence is joining forces with Meltwater to accelerate is leadership in aI-enabled consumer insights
Consolidation continues in the social network monitoring market. Nearly 15 years after its creation, the French company Linkfluence, which helps brands identify weak signals on social networks, is going to continue its story under the American flag. Indeed, it has...
Theranexus presents an update on the progress of its main programs and announces its cash position as of 31 December 2020. Implemantation of a new equity line.
Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells (the “Company”), presents an update on its activities and...
Amolyt Pharma Receives Orphan Drug Designation for AZP-3601 for the Potential Treatment of Hypoparathyroidism
Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and metabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) had granted Orphan Drug Designation (ODD) to AZP-3601, the company’s clinical...
Theranexus, Lyon Neuroscience Research Center and CERMEP announce the creation and funding of new joint public/ private laboratory “NeuroImaging for Drug Discovery” (NI2D)
Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases has announced the creation and funding of a new joint public/private laboratory in partnership with the BIORAN team from the Lyon Neuroscience Research Center (CRNL) and...
Amolyt Pharma announces research collaboration with PeptiDream
Amolyt and Peptidream will collaborate to optimize and evaluate growth hormone receptor antagonists to select a candidate for clinical development as a potential treatment for acromegaly, a rare endocrine disorder. Complete press release Amolyt Pharma
The Food and Drug Administration (FDA) issues a favorable opinion on the preclinical development plan submitted by Theranexus and BBDF
Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases, and the Beyond Batten Disease Foundation (BBDF) announced securement of the favorable opinion of the Food and Drug Administration (FDA) for the continuation of an optimized...
Presentation of the results of the phase IB Clinical study of THN201 for Alzheimer’s disease at the clinical trials on Alzheimer’s disease conference (CTAD)
Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, is pleased to announce the presentation of the results of the...
Theranexus et BBDF obtain European “orphan medicinal product” designation for BBDF-101 in Batten disease
Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases, and the Beyond Batten Disease Foundation (BBDF) today announced the European Commission's decision to award "orphan medicinal product" designation to the two active...
Amolyt Pharma Doses First Subject in Phase 1 Clinical Trial of Parathyroid Hormone Analog, AZP-3601, for Hypoparathyroidism
Amolyt Pharma, a global clinical-stage company specialized in developing therapeutic peptides for rare endocrine and metabolic diseases, today announced that the first subject in the Phase 1 clinical trial for AZP-3601 has been dosed. AZP-3601 is currently in...
Theranexus presents its latest scientific news
Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, is pleased to announce a research partnership with the University...